Evidence map›Paper›PMID 41996413›Full record

ArticleSexually transmitted diseases2026

Comparing Asymptomatic Versus Symptomatic Bacterial Vaginosis: Clinical Characteristics, Vaginal Microbiota, and Lactic Acid Profiles.

Xin He, Golsa M Yazdy, Carl Yeoman, Khalil G Ghanem, Daniel J Erchick, Alexis Taylor, Karen Griffin, Johanna Holm, Jacques Ravel, Rebecca M Brotman and 1 more

Abstract readComparative Study
In one paragraph

Article in Sexually transmitted diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xin HeFrom the Department of Epidemiology and Biostatistics, University of Maryland, College Park, MD.
Golsa M YazdyDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD.
Carl YeomanDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, MT.
Khalil G GhanemDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Daniel J ErchickDepartment of International Health, Center for Human Nutrition, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Alexis TaylorDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Karen GriffinDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Johanna HolmCenter for Advanced Microbiome Research and Innovation, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD.
Jacques RavelCenter for Advanced Microbiome Research and Innovation, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD.
Rebecca M BrotmanCenter for Advanced Microbiome Research and Innovation, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD.
Susan TuddenhamDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.

Funding

Longitudinal Study of the Vaginal Microbiome Prior To Incident STIR01AI116799 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BROTMAN, REBECCA M. · 2015 to 2019
$3.5M
Cervicovaginal microbiome, mucosal immunity, and pathogen factors that contribute to spontaneous clearance of Chlamydia trachomatisR01AI167629 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BROTMAN, REBECCA M., RAVEL, JACQUES · 2022 to 2025
$3.1M
The vaginal microenvironment in asymptomatic versus symptomatic bacterial vaginosisR21AI168984 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TUDDENHAM, SUSAN ANNE · 2023 to 2024
$482k
Integrating multi-omics data: Modeling biomarkers and mechanisms to reduce bacterial vaginosis recurrenceK01AI163413 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HOLM, JOHANNA B. · 2021 to 2025
$464k
Clindamycin treatment for Bacterial Vaginosis: Identifying Subpopulations with EnhancedTherapeutic OutcomesK23AI193080 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Golsa Mirmiran Yazdy · 2025 to 2026
$393k
NIAID NIH HHS K01 AI163413NIAID NIH HHS K23 AI193080NIAID NIH HHS R01 AI116799NIAID NIH HHS R01 AI167629NIAID NIH HHS R21 AI168984
6 · The paper itself

Abstract

backgroundIrrespective of symptoms, bacterial vaginosis (BV) has been linked to increased risk of sexually transmitted infections and HIV, yet clinical guidelines recommend treatment only for symptomatic BV (sBV). We compared demographic, clinical, and vaginal microbiota factors between asymptomatic BV (aBV) and sBV.

methodsData from a previously conducted vaginitis cohort study were analyzed. Participants with Amsel-BV were classified as sBV if they reported vaginal symptoms and aBV if asymptomatic. Nugent scores were assigned. Cervicovaginal lavage fluid underwent 16S rRNA gene amplicon sequencing, broad-range quantitative polymerase chain reaction, and lactic acid isomer quantitative assays. Wilcoxon rank-sum, Fisher exact, and Chi-squared tests compared factors between aBV and sBV. Taxonomic differences were evaluated using elastic net modeling and differential abundance testing.

resultsAmong 70 participants with sBV and 270 with aBV, clinician-assessed abnormal discharge was more common in sBV (86%) than aBV (71%). In adjusted analyses, recent use of metronidazole or clindamycin, more sex partners, and education beyond high school were associated with increased odds for sBV, and injectable contraception with aBV. No consistent differences were observed between sBV versus aBV for other Amsel criteria, Nugent scores, or vaginal microbiota composition. d - and l -lactic acid levels were slightly higher in sBV than aBV.

conclusionsAlthough some demographic, clinical, and behavioral factors differed between sBV and aBV, no consistent differences were found in vaginal microbiota composition; lactic acid isomer levels were low in both groups. Further research is needed to understand why some experience symptoms, to identify whether other biological factors differentiate aBV from sBV, and to evaluate their respective associations with adverse reproductive outcomes.

Indexed as

Lactic AcidMicrobiotaVaginaVaginosis, BacterialAdultCohort StudiesFemaleHumansMetronidazoleRNA, Ribosomal, 16SYoung AdultLactic AcidMetronidazoleRNA, Ribosomal, 16S

Identifiers

PMID41996413
PMCPMC13147338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.